[A25-113] Bulevirtide (chronic hepatitis D) – Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2025
Project no.:
A25-113
Commission:
Commission awarded on 01.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Chronic hepatitis delta virus infection with compensated liver disease
Result of dossier assessment:
- Adults: added benefit not proven
- Children and adolescents 3 to < 18 years of age weighing at least 10 kg: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-113
| Project no. | Title | Status |
|---|---|---|
| G25-02 | Bulevirtide (chronic hepatitis D, children ≥ 3 to < 18 years, ≥ 10 kg) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G20-19 | Bulevirtide (chronic hepatitis delta virus infection) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |